Document is current
Any future updates will be listed below
-
Authors
Ling, Shifeng
Chen, Tienan
Wang, Shaojiao
Zhang, Wei
Zhou, Rujiang
Xia, Xuechun
Yao, Zhengju
Fan, Ying
Ning, Song
Liu, Jiayin
Qin, Lianju
Tucker, Haley O.
Wang, Niansong
Guo, Xizhi https://orcid.org/0000-0001-8047-6049
-
Funding
Funding for this research was provided by:
National Key Research and Development Program of China (2020YFA0803601)
National Natural Science Foundation of China (92068203, 91749103)
Cancer Prevention and Research Institute of Texas (RP100612, RP120348)
National Institute of Health (CA31534)
- License Information
-
More Information
Article History
Received: 19 April 2022
Accepted: 2 May 2023
First Online: 28 July 2023
Declarations
:
: The human umbilical cord mesenchymal stem cells (UMSC 10.2.2) and human embryonic stem cell line CCRM-hESC-22 were approved by the institutional ethics committee of the First Affiliated Hospital of Nanjing Medical University, Nanjing China (Title of the approved project: Construction of Biopsy Bank from Collections of Reproductive Cells, Tissues and Residue Placenta; Name of the institutional approval committee: the First Affiliated Hospital of Nanjing Medical University, Nanjing China; Approval number: 2012-SR-128; Date of approval and consent to participate: Nov. 7, 2013).
: Not applicable.
: The authors declare no competing interests.
